Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited (NASDAQ: NVX, ASX: NVX) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer under Commission File Number 001-41208. On this SEC filings page, Stock Titan surfaces NOVONIX’s regulatory submissions, including Form 6-K current reports that transmit key corporate documents and market announcements.
NOVONIX’s recent Form 6-K filings reference items such as applications for quotation of securities (Appendix 2A), notifications of cessation of securities (Appendix 3H), notifications of issue or conversion of unquoted equity securities (Appendix 3G), changes in substantial holdings, and quarterly activities and cash flow reports. These documents provide detail on NOVONIX’s capital structure changes, equity issuance or cessation events, and operational and cash flow updates.
The company’s filings also identify its principal executive office in Brisbane, Queensland, Australia, and confirm its status as a foreign issuer with securities listed on NASDAQ. Through these filings, NOVONIX reports on matters connected to its battery materials and technology activities, including synthetic graphite manufacturing projects and related financing or governance actions disclosed to investors via attached exhibits.
On Stock Titan, NOVONIX filings are paired with AI-powered summaries that highlight the main points of each document in accessible language. Users can quickly see what type of filing NOVONIX has submitted, the nature of any security issuances or changes, and references to significant corporate announcements included as exhibits. Real-time updates from the EDGAR system, combined with these summaries, help readers navigate NOVONIX’s regulatory history and understand how its SEC reporting aligns with its broader business developments.
Novonix Limited has called its 2026 Annual General Meeting for 15 April 2026 as a hybrid event in Brisbane and online, where shareholders can watch, ask questions and vote virtually or in person.
Key items include receiving the FY25 financial and remuneration reports, advisory approval of the 2025 Remuneration Report, and re-election of directors Admiral Robert Natter and Ronald Edmonds. Shareholders are asked to re-approve the Performance Rights Plan for up to 35,000,000 Performance Rights and to grant CEO Michael O’Kronley 5,862,567 FY26 Performance Rights tied to three-year relative TSR and a 2028 revenue modifier. Resolutions also seek approval for 1,371,566 FY26 Share Rights across Phillips 66 Company and six non-executive directors, and an additional 10% share placement capacity under ASX Listing Rule 7.1A, taking potential placement headroom to 25% if approved.
NOVONIX Ltd’s Chief Financial Officer Robert Buell Long filed an initial ownership report showing his equity-based incentives. The Form 3 lists performance rights that can convert into 1,363,398 ordinary shares expiring in 2028, 2,069,142 shares expiring in 2029, and 1,144,130 shares expiring in 2027, all with a conversion price of $0.0000.
NOVONIX Ltd reported the initial equity holdings of Chief Legal and Risk Officer Kimberly J. Heimert. The filing lists two blocks of performance rights that can convert to ordinary shares at an exercise price of
One block relates to 489,818 underlying ordinary shares with an exercise date on
NOVONIX Ltd Chief Operating Officer Dwayne Arnold Johnson filed an initial ownership report showing he holds several grants of performance rights linked to NOVONIX ordinary shares. These performance rights have a zero exercise price and, if vesting conditions are met, can convert into ordinary shares over multiple future dates.
The holdings include one grant tied to 1,724,285 underlying ordinary shares and another tied to 173,062 underlying shares, with exercise dates at the end of 2028 and 2027, respectively. Additional time-based performance rights cover blocks of 258,883 or 258,884 underlying ordinary shares each, with exercise dates on November 1, 2026, 2027, 2028, and 2029, and expirations generally on November 1, 2030. The filing lists these positions only and does not show any new market purchases or sales.
NOVONIX Ltd filed an initial insider ownership report for Chief Executive Officer Michael O'Kronley. The filing shows he holds performance rights that can be converted into 3,723,971 ordinary shares at an exercise price of $0.0000 per share, with these rights expiring on December 31, 2028. This is a holdings disclosure rather than a new buy or sell transaction.
NOVONIX Ltd director Robert J. Natter has filed a Form 3 reporting his existing ownership of the company’s ordinary shares. The filing shows 230,343 ordinary shares held directly. It also shows indirect ownership through trusts, with 1,365,888 ordinary shares held in a trust where he is trustee and 1,298,758 ordinary shares held in a trust where his spouse is trustee. These entries are reported as holdings, not as new market transactions, and provide a baseline view of his beneficial ownership in NOVONIX.
NOVONIX Ltd director Ronald C. Edmonds has filed an initial Form 3 disclosing his ownership in the company. The filing reports that he directly holds 416,342 ordinary shares as of March 16, 2026. This establishes his starting equity position as a reporting insider under SEC rules.
NOVONIX Ltd director files initial ownership report with no transactions
NOVONIX Ltd director Vaidyanathan Suresh has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The filing does not report any equity transactions or derivative exercises, and shows no derivative positions in the derivative summary section.
NOVONIX Ltd director Jean Oelwang filed an initial Form 3 disclosing current holdings in the company. The filing reports direct ownership of 309,508 ordinary shares of NOVONIX as of the reported date, with no associated purchase, sale, or derivative transactions described.
NOVONIX Ltd director Burrow Sharan has filed an initial ownership report showing a significant personal stake in the company. The Form 3 indicates direct beneficial ownership of 215,739 ordinary shares. This filing establishes Sharan’s starting equity position as a director and does not reflect any specific recent share purchase or sale.